AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 251 min read$BDSX

Biodesix Stock Up Over 90% In Three Months, Hits New 52-Week High

Biodesix (BDSX) hit a 52-week high of $29.18, up over 90% in three months. Q2 2026 revenue rose to $26.9M from $20.1M in Q2 2025, showing growth.

Original reporting
rttnews.com
Published Aug 25, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 5:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BDSX
Bullish
medium confidence
Mentioned
$BDSX
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$BDSXBullishMed
01

Why it matters

The earnings beat and revenue growth have propelled the stock to a new 52‑week high.

02

Market read

Earnings surprise drives significant short‑term price action and may influence sector sentiment.

03

What to watch

Potential regulatory or reimbursement risks not discussed.

Relevance 6/10Novelty 7/10Timing: today's trading

Background

Biodesix is a US‑listed diagnostic company focusing on lung disease biomarkers.

Company-level read

Ticker impact

$BDSXBullishMedium confidence
Context

Biodesix reported Q2 2026 revenue of $26.9M, up from $20.1M a year earlier, driving a 90% price surge.

Expected impact

Potential continuation of rally if guidance remains upbeat.

Evidence & confidence

Quarterly top‑line growth exceeds prior year and coincides with a sharp price jump, indicating momentum.

Market effects

Sector

Highlights growth in the lung‑diagnostics segment, may lift peer biotech stocks.

Regional

Positive for US small‑cap biotech sector.

Global

Limited to niche diagnostic market.

Counterpoint

What could challenge this read

Revenue size remains modest; price may be overextended after a 90% rally.

Key entities

  • company
    Biodesix, Inc.

    Diagnostic solutions provider reporting Q2 2026 results.

Read at source← All news

Related articles

AUG 14
$BDSXMedAI 8/10

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.

yahoo.com7 min
AUG 5
$BDSXHigh

BIODESIX INC (BDSX): Results of Operations and Financial Condition

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere

SEC EDGAR 8-K4 min
SEP 18
$UNFIMedAI 8/10

United Natural Foods (UNFI) Calls the Bottom and Guides for Growth Again

United Natural Foods (UNFI) reported Q4 adjusted EPS of $0.69, beating estimates, but revenue of $7.64B missed expectations. The company guided fiscal 2027 sales to $31.2B-$31.8B, up from $31.15B in 2026. Adjusted EBITDA rose 27% to $701M, and free cash flow hit a record $323M. Management expects fiscal 2027 adjusted EPS of $3.00-$3.50. Hedge fund interest declined in Q2.

insidermonkey.com3 min